公开(公告)号：US20240060085A1

公开(公告)日：2024-02-22

申请号：US17818508

申请日：2022-08-09

Applicant: GEG TECH

Inventor： Nicolas GRANDCHAMP

IPC: C12N15/86 ,  A61K31/7105 ,  A61K38/46 ,  C12N15/85 ,  C12N15/90

CPC classification number: C12N15/86 ,  A61K31/7105 ,  A61K38/465 ,  C12N15/8509 ,  C12N15/907 ,  A61K48/00 ,  C12N2740/16043 ,  C12N2740/16071

Abstract: A method of therapeutic treatment by genome engineering in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5′ to 3′ an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: m″ indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one genome editor.

公开(公告)号：US20230312658A1

公开(公告)日：2023-10-05

申请号：US18067525

申请日：2022-12-16

Applicant: Centivax, Inc.

Inventor： Jacob E. Glanville

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K38/46 ,  G16B30/10 ,  A61K39/00 ,  G16C20/60 ,  C12N7/00 ,  G16B35/00 ,  G16B20/30 ,  G16B30/00 ,  G16B35/10 ,  G16B20/00

CPC classification number: C07K14/005 ,  A61K38/46 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  G16B20/30 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16B35/10 ,  G16C20/60 ,  A61K2039/515 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12Y306/05002 ,  G16B20/00

Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

公开(公告)号：US10034933B2

公开(公告)日：2018-07-31

申请号：US15588476

申请日：2017-05-05

Applicant: PepTcell, Ltd.

Inventor： Gregory Alan Stoloff ,  Wilson Romero Caparros-Wanderlay

IPC: A61K39/21 ,  A61K39/12 ,  C07K14/16 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/55544 ,  C07K14/005 ,  C07K2319/01 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16322 ,  C12N2740/16334

Abstract: The present specification discloses an immunogenic composition comprising polypeptide, wherein each of the polypeptides has no more than 100 amino acids, which polypeptides comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope, wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.

公开(公告)号：US20180036400A1

公开(公告)日：2018-02-08

申请号：US15320432

申请日：2015-06-25

Applicant: DUKE UNIVERSITY

Inventor： Barton F Haynes ,  Hua-Xin Liao ,  S. Munir Alam

IPC: A61K39/21 ,  C07K14/005

CPC classification number: A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: In certain aspects the invention provides HIV-1 engineered envelope proteins and their uses. The engineered envelopes comprise a sequence that prevents cleavage of the envelope associated with recombinant expression in a cell line, and N-terminal deletion which improves envelope expression as a monomer.

公开(公告)号：US20170312490A1

公开(公告)日：2017-11-02

申请号：US15592380

申请日：2017-05-11

Applicant: MuPharma Pty Ltd

Inventor： Harry Unger ,  Mark Unger ,  Sean Michael Langelier

IPC: A61M37/00 ,  A61K39/21 ,  C12N7/00 ,  A61K41/00 ,  A61K39/00

CPC classification number: A61M37/0092 ,  A61K39/12 ,  A61K39/21 ,  A61K41/0047 ,  A61K2039/5256 ,  A61K2039/54 ,  A61M37/0015 ,  A61M2037/0007 ,  A61M2037/0023 ,  A61M2205/3344 ,  A61M2205/3375 ,  A61N1/30 ,  A61N7/00 ,  C12N7/00 ,  C12N2710/24021 ,  C12N2710/24043 ,  C12N2710/24143 ,  C12N2740/16034 ,  C12N2740/16071

Abstract: There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.

公开(公告)号：US09757587B2

公开(公告)日：2017-09-12

申请号：US13208419

申请日：2011-08-12

Applicant: Karl Deisseroth ,  Feng Zhang ,  Viviana Gradinaru

Inventor： Karl Deisseroth ,  Feng Zhang ,  Viviana Gradinaru

IPC: C12N13/00 ,  A61N5/06 ,  A01K67/033 ,  A61K48/00 ,  C07K14/195 ,  C07K14/215 ,  C12N15/86 ,  C07K14/00 ,  A61K38/00

CPC classification number: A61N5/062 ,  A01K67/0333 ,  A01K2217/052 ,  A01K2227/703 ,  A01K2267/0356 ,  A61K38/00 ,  A61K48/005 ,  A61K48/0058 ,  A61K48/0083 ,  A61N5/0613 ,  A61N5/0622 ,  C07K14/00 ,  C07K14/195 ,  C07K14/215 ,  C12N13/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/16643 ,  C12N2740/16043 ,  C12N2740/16071 ,  C12N2750/14143 ,  C12N2830/002

Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated NpHR-based molecule comprising a nucleic acid sequence that codes for light-activated NpHR-based molecule and a promoter. Either a high expression of the molecule manifests a toxicity level that is less than about 75%, or the light-activated NpHR-based proteins are expressed using at least two NpHR-based molecular variants. Each of the variants characterized in being useful for expressing a light-activated NpHR-based molecule that responds to light by producing an inhibitory current to dissuade depolarization of the neuron. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion pumps or for controlling inhibitory currents in a cell (e.g., in in vivo and in vitro environments).

公开(公告)号：US20170202949A1

公开(公告)日：2017-07-20

申请号：US15394206

申请日：2016-12-29

Applicant: Providence Health & Services - Oregon

Inventor： Hong-Ming Hu

IPC: A61K39/21 ,  C12N7/00 ,  A61K31/436 ,  A61K39/395 ,  C07K16/28 ,  A61K31/69 ,  A61K39/00 ,  A61K38/19

CPC classification number: A61K39/21 ,  A61K31/436 ,  A61K31/69 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/5152 ,  A61K2039/5154 ,  C07K16/2875 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16071

Abstract: Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject.

公开(公告)号：US09675686B2

公开(公告)日：2017-06-13

申请号：US14656690

申请日：2015-03-12

Applicant: PepTcell, Ltd.

Inventor： Gregory Alan Stoloff ,  Wilson Romero Caparros-Wanderlay

IPC: A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  C07K14/005 ,  A61K39/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/55544 ,  C07K14/005 ,  C07K2319/01 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16322 ,  C12N2740/16334

Abstract: The present specification discloses an immunogenic composition comprising polypeptide, wherein each of the polypeptides has no more than 100 amino acids, which polypeptides comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope,wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.

公开(公告)号：US09630996B2

公开(公告)日：2017-04-25

申请号：US14368102

申请日：2012-12-21

Applicant: THE UNIVERSITY OF WESTERN ONTARIO

Inventor： Chil-Yong Kang ,  Gyoung Nyoun Kim

IPC: A61K39/205 ,  A61K39/00 ,  C07K14/145 ,  C12N7/04 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

CPC classification number: A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

Abstract: The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

公开(公告)号：US09216214B2

公开(公告)日：2015-12-22

申请号：US14571942

申请日：2014-12-16

Applicant: The United States of America as represented by the Secretary of the Department of Health and Human Services ,  Istituto Superiore di Sanità

Inventor： Bo Peng ,  Rebecca Voltan ,  Barbara Ensoli ,  Marjorie Robert-Guroff

IPC: A61K39/21 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

CPC classification number: C12N15/86 ,  A61K39/21 ,  A61K2039/5256 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/16143 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16334

Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.